Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE
. Clopidogrel versus aspirin in patients at risk of ischemic events.
And while clopidogrel alone resulted in a 24% reduction in vascular events compared with aspirin in patients with PAD in the nearly 20,000-patient Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE
) trial, the number needed to treat for 1 year to prevent one vascular event was 165.
Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE
and CURE studies.
In the Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events (CURE) study and in the Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE
) study, there was an increased risk of bleeding and a decreased benefit with concomitant use of clopidogrel with aspirin compared with aspirin alone in patients aged 75 years and older, according to an FDA spokesperson.
The Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE
) trial evaluated clopidogrel (75 mg once daily) versus aspirin (325 mg once daily) in reducing the risk of the combined outcome of ischemic stroke, MI, or vascular death in more than 19,000 patients who entered the trial with recent ischemic stroke, recent MI, or symptomatic peripheral vascular disease.